Fundacion Centro Nacional De Investigaciones Oncologicas Carlos III

Centro Nacional De Investigaciones Oncologicas (cnio)

Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncologicas Carlos III (f.s.p. Cnio)

Fundacion Del Sector Publico Estatal Centro Nacional De Investigaciones Oncologicas Carlos III

Sonia Martínez González

Joaquin Pastor Fernandez

Joaquin Pastor Fernández

Joaquín Pastor Fernández

Jose Ignacio Martín Hernando

Antonio Rodríguez Hergueta

Carmen Blanco Aparicio

Francisco Javier Ramos Lima

Ana Isabel Hernández Higueras

Guido Kurz

Rosario Concepción Riesco Fagundo

Julen Oyarzabal Santamarina

Ana Maria Garcia Collazo

Rosa Maria Álvarez Escobar

Rosa Maria Alvarez Escobar

Oliver Renner

Matilde Murga Costa

María Nieto Soler

David Alvaro Cebrián Muñoz

Andrés Joaquín Lopez Contreras

Carmen Varela Busto

Sonsoles Rodríguez Arísteguí

Luis Ignacio Toledo Lázaro

Oscar Fernández-Capetillo Ruiz

María Del Rosario Rico Ferreira

Carmen Blanco-Aparicio

Cristina Ana Gómez De La Oliva

Virginia Rivero Buceta

Manuel Serrano Marugan

Ana Ortega Molina

James R Bischoff

Carl-Gustave Pierre Saluste

Esther Gonzalez Cantalapiedra

Antonio Salgado Serrano

Beatriz Noya Marino

Antonio Cebriá Gómez

Beatriz Noya Mariño

Sonsoles RODRÍGUEZ Aristegui

Esther GONZÁLES Cantalapiedra

Rosa María Alvarez Escobar

José Ignacio MARTÍN Hernando

Rosa María ÁLvarez Escobar

David ÁLvaro CEBRIÁN MUÑOZ

Ana Belén GARCÍA GARCÍA

Rosario Concepcion Riesco Fagundo

Cristina Ana Gomez De La Oliva

Ana Isabel Hernandez Higueras

Elena Hernández Encinas

Esther González Cantalapiedra

María Isabel Albarrán Santiño

There is provided compounds of formula I, wherein R, R, RR, R, R, Rand Rhave meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8 and/or Haspin kinase) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

Condensed tricyclic compounds as protein kinase inhibitors

The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-&#x3b1; (Pgd1&#x3b1;) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.

Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing

There is provided compounds of formula (I), wherein R, R, Rand Rhave meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I). 

Tricyclic compounds for use as kinase inhibitors

Provided are chemical entities selected from compounds of formula (I), wherein R, Rand m have meanings given in the description, and pharmaceutically acceptable salts, solvates and stereoisomers thereof, which are inhibitors of ATR and are potentially useful in the treatment of cancer. Further provided are pharmaceutical compositions of the chemical entities, combination products containing the chemical entities, the use of the compositions as therapeutic agents, and methods of treatment using these compositions. 

Chemical entities

There is provided compounds of formula (I), wherein A, A, A, A, B, B, B, B, B, B, B, Band Rhave meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. 

Inhibitors of PI3 kinase

There is provided compounds of formula (I): wherein R, Rand Rhave meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K) is desired and/or required, and particularly in the treatment of cancer. 

Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives

Growing community of inventors

Madrid, Spain

Sonia Martínez González